
    
      This trial is planned to be conducted simultaneously in multiple domestic clinical research
      site, and a total of 84 subjects will be enrolled, including 42 subjects in the
      investigational drug group and 42 subjects in the placebo group.

      Primary endpoint: LVESVI change from baseline on day 30 Secondary endpoints: LVEF Change from
      baseline on day 30 and day 90. LVESV, LVEDV, LVEDVI change from baseline on day 30. LVESV,
      LVESVI, LVEDV, LVEDVI change from baseline on day 90. NT-proBNP change from baseline on day
      30 and day 90. NYHA class change from baseline on day 30 and day 90.
    
  